Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 206 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IB Non-small Cell Lung Cancer Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Durvalumab, Copanlisib
Drug
Lead sponsor
Zhonglin Hao
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 21, 2026, 8:08 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sotorasib and Tarloxotinib
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 8:08 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions
GDC-1971, Osimertinib, Cetuximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Camonsertib
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Las Vegas, Nevada • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
Interventions
GEN-001, Avelumab
Drug
Lead sponsor
Genome & Company
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Belinostat, carboplatin, paclitaxel and bevacizumab
Drug
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced May 21, 2026, 8:08 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy treatment planning/simulation, implanted fiducial-based imaging
Radiation · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced May 21, 2026, 8:08 PM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced May 21, 2026, 8:08 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
Interventions
DKY709, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
113
States / cities
Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced May 21, 2026, 8:08 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced May 21, 2026, 8:08 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan, Telemedicine
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Cetuximab in combination with Carboplatin/Gemcitabine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced May 21, 2026, 8:08 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
Interventions
DCVax-Direct
Biological
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced May 21, 2026, 8:08 PM EDT